BioAtla, Inc. (NASDAQ:BCAB) – Equities researchers at Jefferies Financial Group issued their FY2020 earnings estimates for BioAtla in a research report issued on Monday, January 11th. Jefferies Financial Group analyst B. Amin expects that the company will post earnings of ($1.33) per share for the year. Jefferies Financial Group has a “Buy” rating and a $51.00 price objective on the stock. Jefferies Financial Group also issued estimates for BioAtla’s Q1 2021 earnings at ($0.47) EPS, Q2 2021 earnings at ($0.52) EPS, Q3 2021 earnings at ($0.60) EPS, Q4 2021 earnings at ($0.43) EPS, FY2021 earnings at ($2.02) EPS, FY2022 earnings at ($2.43) EPS, FY2023 earnings at ($2.73) EPS, FY2024 earnings at ($4.76) EPS and FY2025 earnings at ($2.94) EPS.
Other equities analysts have also issued research reports about the stock. BTIG Research began coverage on shares of BioAtla in a report on Monday. They issued a “buy” rating and a $47.00 price target for the company. Credit Suisse Group began coverage on shares of BioAtla in a report on Monday. They issued an “outperform” rating and a $49.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on shares of BioAtla in a report on Monday. They issued an “overweight” rating and a $45.00 price target for the company.
In other BioAtla news, major shareholder Cormorant Asset Management, Lp purchased 800,000 shares of the business’s stock in a transaction on Friday, December 18th. The shares were purchased at an average cost of $18.00 per share, with a total value of $14,400,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Guy Levy purchased 1,388,890 shares of the business’s stock in a transaction on Friday, December 18th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $25,000,020.00. The disclosure for this purchase can be found here.
BioAtla Company Profile
BioAtla, Inc, a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types.
See Also: What is the balance sheet?
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.